文献速递其他结缔组织病

SSa/SSb与Ro52抗体在特发性炎性肌病临床表型界定中的差异化作用

The differential role of SSa/SSb and Ro52 antibodies in defining clinical phenotypes in idiopathic inflammatory myopathies.
PubMed 文献 · Semin Arthritis Rheum · 2024-02-08

该回顾性分析纳入94例特发性炎性肌病患者,比较抗SSa/SSb与抗Ro52阳性者的临床表型。作者认为两种抗体均有助于评估ILD风险,但抗Ro52对严重ILD的预测性更强。

要点

  • 抗SSa/SSb阳性者ILD发生率58% vs 阴性者25%(p=0.003)。
  • 抗Ro52阳性者DLCO 47% vs 阴性者68%(p=0.003)。

核心结论

  • 在特发性炎性肌病中,抗SSa/SSb或抗Ro52阳性与较高的ILD发生率相关。
  • 两种检测均有助于评估ILD风险,但抗Ro52对严重ILD的预测性更强。
  • 所有亚组中均观察到骨质疏松和静脉血栓栓塞症(VTE)发生率较高。

研究设计与样本

  • 回顾性分析2007年至2018年在Northwell肌炎中心就诊、符合2017年EULAR/ACR标准且有抗SSa/SSb数据的18岁以上特发性炎性肌病患者。
  • 抗SSa/SSb阴性且抗Ro52阳性的患者被排除在抗SSa/SSb亚组分析之外,但纳入Ro52亚组分析。
  • 记录器官表现、肺功能测试(PFTs)和合并症,统计分析采用卡方检验、Fisher精确检验、Wilcoxon秩和检验、McNemar检验。

主要发现

  • 最终分析纳入94例患者,35%(33/94)为抗SSa/SSb阳性。
  • 60例有抗Ro52数据的患者中,42%(25/60)为阳性。
  • 抗SSa/SSb阳性与基于肺功能测试的ILD严重程度增加无关。
  • 抗Ro52阳性组DLCO低于抗Ro52阴性组(47% vs 68%;p=0.003)。

关键数值与推荐

  • 抗SSa/SSb阳性者ILD发生率58% vs 阴性者25%(p=0.003)。
  • 抗Ro52阳性者DLCO 47% vs 阴性者68%(p=0.003)。
  • 静脉血栓栓塞症(VTE)发生率10%-12%,骨质疏松发生率13-17%,独立于抗SSa/SSb或抗Ro52状态。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In idiopathic inflammatory myopathies, anti-SSa/SSb and anti-Ro52 are associated with interstitial lung disease (ILD), yet few studies have compared their prognostic utility. Our study analyzes clinical phenotypes associated with anti-SSa/SSb and anti-Ro52 positivity in IIM and their association with ILD. METHODS: We performed a retrospective analysis of IIM patients >18-years-old, seen at Northwell Myositis Center 2007- 2018 who met 2017 EULAR/ACR criteria with available anti-SSa/SSb data. Patients who were anti-SSa/SSb(-) and anti-Ro52(+) were excluded from anti-SSa/SSb subgroup analysis but included in Ro52 subgroup analysis. Organ manifestations, pulmonary function tests (PFTs) and comorbidities were recorded. Statistical analyses included Chi-square, Fisher's Exact, Wilcoxon Rank Sum, McNemar's test. RESULTS: Of 94 patients included in the final analysis, 35% (33/94) were anti-SSa/SSb positive (+). Of 60 patients with anti-Ro52 data, 42% (25/60) were (+). ILD was more common in anti-SSa/SSb (+) versus anti-SSa/SSb negative patients and anti-Ro52(+) versus anti-Ro52 negative patients (58% vs 25%; p = 0.003 and 64% vs.26%; p = 0,004 respectively). Anti-SSa/SSb (+) was not associated with increased ILD severity based on PFTs. Anti-Ro52(+) group had lower DLCO than anti-Ro52(-) (47% vs 68%; p = 0.003). Anti-SSa/SSb positivity did not confer a difference in the frequency of other manifestations. Elevated rates of venous thromboembolism (VTE) (10%-12%) and osteoporosis (13-17%) were observed independent of anti-SSa/SSb or anti-Ro52 status. CONCLUSION: In IIM anti-SSa/SSb or anti-Ro52 positivity is associated with higher ILD rate. Both assays are useful to confer ILD risk, but anti-Ro52 is more predictive of severe ILD. High frequencies of osteoporosis and VTE were observed in all subgroups.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Valle A, Narain S, Barilla-Labarca ML, et al. The differential role of SSa/SSb and Ro52 antibodies in defining clinical phenotypes in idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2024. PMID: 38377624. doi:10.1016/j.semarthrit.2024.152407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。